by Biotechnology Focus •
April 25, 2016 •
Business Focus, Oncology, Orphan drugs, Policy/Regulatory/IP, Science Focus •
Comments (0) •
VANCOUVER, BC- The FDA Office of Orphan Products Development (OOPD) has granted an orphan drug designation to DelMar Pharmaceuticals Inc. for its lead product candidate, VAL-083, in the treatment of ovarian cancer.
Comments are closed.
© 2017 Biotechnology Focus™
Powered by Wordpress. Designed by Themnific™